{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T17:06:48Z","timestamp":1720372008664},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jviromet.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T15:24:49Z","timestamp":1442849089000},"page":"76-86","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate"],"prefix":"10.1016","volume":"225","author":[{"given":"Bin","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadas","family":"Dvory-Sobol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Greenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"McCarville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdeleine","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2015.09.002_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","article-title":"Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome","volume":"20","author":"Alter","year":"2000","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0015","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1128\/JVI.67.7.3835-3844.1993","article-title":"Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3\/4 and NS4\/5 junctions","volume":"67","author":"Bartenschlager","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0020","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3390\/v2081752","article-title":"Hepatitis C virus NS3\/4A protease inhibitors: a light at the end of the tunnel","volume":"2","author":"Chatel-Chaix","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0025","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.addr.2007.04.016","article-title":"Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus","volume":"59","author":"De Francesco","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0030","first-page":"584A","volume":"56","author":"Dvory-Sobol","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0035","series-title":"63rd Annual Meeting of the American Association for the Study of the Liver Diseases","article-title":"Persistence of resistance-associated mutations after 3 days of monotherapy with NS3 protease inhibitor GS-9451 in genotype 1 HCV patients [Poster Number 804]","author":"Dvory-Sobol","year":"2012"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0040","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1016\/S0168-8278(12)61187-8","volume":"56","author":"Dvory-Sobol","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0045","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1128\/AAC.00780-12","article-title":"Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients","volume":"56","author":"Dvory-Sobol","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11531990-000000000-00000","article-title":"Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b","volume":"70","author":"Foster","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0055","series-title":"61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)","article-title":"Safety, pharmacokinetics and antiviral activity of single oral doses of the HCV NS3 protease inhibitor GS-9256 [Poster Abstract 824]","author":"Goldwater","year":"2010"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0060","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterization of hepatitis C virus genotype 1\u20137 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs","volume":"49","author":"Gottwein","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0065","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/JVI.67.5.2832-2843.1993","article-title":"Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites","volume":"67","author":"Grakoui","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0070","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/JVI.67.3.1385-1395.1993","article-title":"Expression and identification of hepatitis C virus polyprotein cleavage products","volume":"67","author":"Grakoui","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0075","doi-asserted-by":"crossref","first-page":"e39163","DOI":"10.1371\/journal.pone.0039163","article-title":"The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function","volume":"7","author":"Hebner","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0080","series-title":"AASLD","article-title":"Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results [Slides S05]","author":"Hezode","year":"2012"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0085","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1128\/JVI.02698-09","article-title":"Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6","volume":"84","author":"Imhof","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-0032-1331765","article-title":"Molecular design, synthesis and cell based HCV replicon assay of novel benzoxazole derivatives","volume":"63","author":"Ismail","year":"2013","journal-title":"Drug Res."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0095","series-title":"48th European Association for the Study of the Liver (EASL)","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for chronic hCV genotype 1 infection in treatment-na\u00efve patients: results from QUEST-1, a Phase III trial [Presentation 10]","author":"Jacobson","year":"2013"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0100","first-page":"427A","article-title":"Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 advance study [Abstract 211]","volume":"52","author":"Jacobson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0105","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0110","doi-asserted-by":"crossref","DOI":"10.1007\/s00535-013-0770-9","article-title":"Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region","author":"Kim","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-59745-394-3_4","article-title":"Nomenclature and numbering of the hepatitis C virus","volume":"510","author":"Kuiken","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0125","first-page":"236A","article-title":"A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicons [Abstract 87] Presented at AASLD 2012","volume":"56","author":"Lahser","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0130","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0135","doi-asserted-by":"crossref","first-page":"12334","DOI":"10.1128\/JVI.05639-11","article-title":"Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA","volume":"85","author":"Lam","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0140","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1128\/AAC.00399-10","article-title":"PSI-7851, a pronucleotide of beta-d-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication","volume":"54","author":"Lam","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0145","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/JVI.77.2.1092-1104.2003","article-title":"Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons","volume":"77","author":"Lanford","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0155","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0160","series-title":"45th Annual Meeting of the European Association for the Study of the Liver (EASL)","article-title":"Dose-ranging, three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256 [Poster Presentation]","author":"Lawitz","year":"2010"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0165","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0170","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","article-title":"Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)","volume":"58","author":"Lenz","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0175","first-page":"31","article-title":"Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma","volume":"51","author":"Leone","year":"2005","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0180","series-title":"EASL 45th Annual Meeting","article-title":"MK-5172: a novel HCV NS3\/4A protease inhibitor with potent activity against known resistance mutants [Presentation]","author":"Liverton","year":"2010"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0190","series-title":"48th European Association for the Study of the Liver (EASL), Amsterdam, NL","article-title":"Simeprevir (TMC435) with peginterferon-\u03b12a or -\u03b12b and ribavirin in treatment-na\u00efve HCV genotype 1 patients: QUEST-2, a randomised Phase III trial [Presentation 18]","author":"Manns","year":"2013"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0195","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0168-8278(11)60128-1","article-title":"A phase-2B trial to evaluate the safety, tolerability and efficacy of a caspase inhibitor, GS-9450, in adults failing PEG\/RBV therapy for chronic HCV infection [Abstract 126]","volume":"54","author":"Manns","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0200","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2010.08.040","article-title":"Potency, safety, and pharmacokinetics of the NS3\/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection","volume":"54","author":"Manns","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0205","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0210","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0215","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0220","first-page":"186","article-title":"Antiviral activity and viral resistance in genotype 1 HCV patients receiving 28-day combination treatment with GS-9256 and tegobuvir\u00b1RBV\u00b1PEG followed by PEG\/RBV therapy [Abstract PP13-095]","volume":"6","author":"Mo","year":"2012","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0225","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(12)60026-9","article-title":"High SVR12 with 16 weeks of tegobuvir and GS-9256 with peginterferon-alpha 2A and ribavirin in treatment-naive genotype 1 HCV patients [Abstract #12]","volume":"56","author":"Nelson","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0230","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.09.033","article-title":"Development of robust hepatitis C virus genotype 4 subgenomic replicons","volume":"144","author":"Peng","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0235","series-title":"Presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)","article-title":"Safety and antiviral activity of MK-5172, a novel HCV NS3\/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 hcv-infected patients [Poster Abstract]","author":"Petry","year":"2010"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0240","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/JVI.75.3.1252-1264.2001","article-title":"Characterization of cell lines carrying self-replicating hepatitis C virus RNAs","volume":"75","author":"Pietschmann","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0245","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0250","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0255","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.antiviral.2008.11.002","article-title":"Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates","volume":"81","author":"Qi","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0260","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1073\/pnas.1101515108","article-title":"Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals","volume":"108","author":"Robinson","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0265","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4254\/wjh.v4.i12.342","article-title":"Hepatitis C virus-related hepatocellular carcinoma: an insight into molecular mechanisms and therapeutic strategies","volume":"4","author":"Selimovic","year":"2012","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0270","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1582-4934.2011.01304.x","article-title":"Apoptosis related protein-1 triggers melanoma cell death via interaction with the juxtamembrane region of p75 neurotrophin receptor","volume":"16","author":"Selimovic","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0275","article-title":"Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3\/4A protease","author":"Sheng","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"Suppl. 1","key":"10.1016\/j.jviromet.2015.09.002_bib0280","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0168-8278(99)80375-4","article-title":"Viral heterogeneity of the hepatitis C virus","volume":"31","author":"Simmonds","year":"1999","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0285","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","article-title":"Genetic diversity and evolution of hepatitis C virus \u2013 15 years on","volume":"85","author":"Simmonds","year":"2004","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0290","series-title":"The Liver Meeting 2012: 63rd Annual Meeting of the AASLD","author":"Sulkowski","year":"2012"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0295","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","author":"Summa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0300","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/JCM.00838-12","article-title":"Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy","volume":"50","author":"Svarovskaia","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0305","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1128\/JVI.67.7.4017-4026.1993","article-title":"NS3 is a serine protease required for processing of hepatitis C virus polyprotein","volume":"67","author":"Tomei","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0310","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0166-0934(03)00134-4","article-title":"A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C","volume":"110","author":"Vrolijk","year":"2003","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0315","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.virol.2012.03.025","article-title":"Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a","volume":"429","author":"Wong","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0320","series-title":"61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA","article-title":"Chracterization of HCV resistance from single and multiple dose clinical trials of GS-9256, a novel NS3 protease inhibitor [Poster Abstract 1876]","author":"Wong","year":"2010"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0325","series-title":"EASL 46th Annual Meeting","article-title":"Genotypic and phenotypic characterization of HCV resistance from a multiple dose clinical trial of GS-9451, a novel NS3 protease inhibitor [Poster Abstract 1073]","author":"Wong","year":"2011"},{"key":"10.1016\/j.jviromet.2015.09.002_bib0330","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S1386-6532(06)80339-2","article-title":"A novel fluorescence-based protease assay using the endogenous NS3\/4A protease activity present in the total cell lysates of HCV replicon cells [abstract P.159]","volume":"36","author":"Yang","year":"2006","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jviromet.2015.09.002_bib0335","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24744","article-title":"The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C","volume":"55","author":"Zeuzem","year":"2012","journal-title":"Hepatology"}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093415003079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093415003079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T15:00:58Z","timestamp":1599577258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093415003079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":66,"alternative-id":["S0166093415003079"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2015.09.002","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}